促红细胞生成素治疗新生儿缺氧缺血性脑病:一项随机临床试验
PAEAN研究为3期多中心双盲安慰剂对照随机临床试验,纳入313名胎龄≥35周、接受亚低温治疗的中重度HIE患儿,评估促红细胞生成素(EPO)联合亚低温的疗效。结果显示EPO组与安慰剂组在2岁时死亡或中重度运动/认知残疾复合结局无显著差异(34.1% vs 28.7%;RR 1.19;95%CI 0.84-1.68;
要点
- EPO联合亚低温未改善中重度HIE患儿2岁时死亡或残疾复合结局。
- EPO组与安慰剂组在死亡、脑瘫、运动缺陷、认知缺陷等继发结局无显著差异。
- 未观察到EPO相关安全性问题。
核心结论
- EPO联合亚低温对中重度HIE患儿无附加疗效,但未发现安全性顾虑。
研究设计与样本
- PAEAN研究为3期多中心双盲安慰剂对照随机临床试验,在澳大利亚、新西兰和新加坡24个NICU开展。
- 纳入胎龄≥35周、生后<23小时、存在围产期抑制且符合改良Sarnat中重度HIE标准、生后6小时内开始亚低温治疗的患儿。
- 2016年5月至2021年3月招募,共随机313名婴儿(EPO组156例,安慰剂组157例)。
- 干预为静脉EPO 1000 IU/kg,第一周内给药5次,或安慰剂。
主要发现
- 脑瘫:EPO组22/120(18.3%)vs 安慰剂组22/127(17.3%)。
- 运动缺陷:EPO组13/120(10.8%)vs 安慰剂组15/127(11.8%)。
- 认知缺陷:EPO组20/113(17.7%)vs 安慰剂组16/118(13.6%)。
关键数值与推荐
- 主要结局采用标准化神经发育评估,中重度残疾定义为脑瘫伴粗大运动功能分类系统评分≥2或Bayley婴幼儿发育量表第三版中重度认知缺陷。
- 纳入标准包括脐动脉血pH<7.0或碱剩余≥12 mmol/L,或10分钟Apgar评分≤5,或仍需要复苏。
临床怎么用
- 基于现有证据,不推荐在亚低温治疗基础上常规加用EPO改善中重度HIE患儿的2岁神经发育结局。
局限性
- 随访失访率总体为10.2%,可能影响结果解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Therapeutic hypothermia (TH) is the standard of care to improve outcomes following neonatal hypoxic-ischemic encephalopathy (HIE), but mortality and morbidity remain high, prompting research into treatment adjuncts. OBJECTIVE: To assess whether erythropoietin (EPO) plus TH improves outcomes in infants with moderate or severe HIE. DESIGN, SETTING, AND PARTICIPANTS: The PAEAN (Preventing Adverse Outcomes of Neonatal Hypoxic Ischaemic Encephalopathy with Erythropoietin) study was a phase 3, multicenter, double-blinded, placebo-controlled randomized clinical trial conducted in 24 neonatal intensive care units in Australia, New Zealand, and Singapore. Infants 35 weeks' gestation or older, less than 23 hours old, with perinatal depression (umbilical cord arterial pH <7.0 or base excess ≥12 mmol/L or, at 10 minutes, Apgar score ≤5 or still receiving resuscitation), and moderate or severe HIE (modified Sarnat criteria) who had commenced TH within 6 hours of birth were eligible for inclusion. Study recruitment was conducted between May 2016 and March 2021, with data collection completed in September 2024. Data analysis was performed from September 2024 to October 2025. INTERVENTION: Intravenous EPO, 1000 IU/kg (5 doses over the first week), or placebo. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of death or moderate or severe motor or cognitive disability using standardized neurological and developmental assessments at 2 years. Moderate or severe disability comprised motor deficit (diagnosis of cerebral palsy with Gross Motor Function Classification Scale score ≥2) or moderate or severe cognitive deficit using Bayley Scales of Infant Development, Third Edition. Secondary outcomes included death, disabilities alone, and safety. RESULTS: From 2016 to 2021, 313 infants were randomized (EPO: n = 156; placebo: n = 157). Baseline characteristics (including mean [SD] gestational age at birth: 39.4 [1.7] weeks vs 39.3 [1.6] weeks and ratio of moderate:severe encephalopathy: 78%:22% vs 77%:23%) and loss to follow-up (10.2% overall) were similar across both groups. There were 67 (42.9%) and 59 (37.6%) female infants, respectively. There was no significant difference in the primary outcome (EPO: 47 of 138 [34.1%] vs placebo: 41 of 143 [28.7%]; relative risk, 1.19; 95% CI, 0.84-1.68; P = .33), in secondary outcomes (death: 22 of 146 [15.1%] vs 18 of 149 [12.1%]; P = .45; cerebral palsy: 22 of 120 [18.3%] vs 22 of 127 [17.3%]; motor deficit: 13 of 120 [10.8%] vs 15 of 127 [11.8%]; cognitive deficit: 20 of 113 [17.7%] vs 16 of 118 [13.6%]), or in any safety outcomes. CONCLUSIONS AND RELEVANCE: Per the results of this multicenter randomized clinical trial, EPO did not demonstrate any adjunctive effect to hypothermia, but no safety concerns were evident. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12614000669695.
引用
- Liley HG, Hunt RW, O'Connell RL, et al. Erythropoietin for Neonatal Hypoxic-Ischemic Encephalopathy: A Randomized Clinical Trial. JAMA Pediatr. 2026. PMID: 42507461. doi:10.1001/jamapediatrics.2026.3082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。